Compare RENT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | KPTI |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 148.0M |
| IPO Year | 2021 | 2013 |
| Metric | RENT | KPTI |
|---|---|---|
| Price | $8.04 | $6.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 238.4K | ★ 413.6K |
| Earning Date | 12-12-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $314,500,000.00 | $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | $3.32 | ★ N/A |
| Revenue Growth | ★ 2.91 | N/A |
| 52 Week Low | $3.69 | $3.51 |
| 52 Week High | $10.13 | $10.80 |
| Indicator | RENT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 39.97 |
| Support Level | $8.45 | $7.05 |
| Resistance Level | $10.13 | $8.95 |
| Average True Range (ATR) | 0.82 | 0.62 |
| MACD | -0.14 | -0.18 |
| Stochastic Oscillator | 11.51 | 1.85 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.